Related Experiment Videos

[Elderly patients with cardiovascular diseases]

U Müller-Werdan1, M Meisel, P Schirdewahn

  • 1Universitätsklinik und Poliklinik für Innere Medizin III, Universitätsklinikum der Martin-Luther-Universität Halle-Wittenberg, Ernst-Grube-Strasse 40, 06097, Halle/Saale, Deutschland. ursula.mueller-werdan@medizin.uni-halle.de

Der Internist
|October 18, 2007
PubMed

Insights

Cardiovascular disease in the elderly presents with atypical symptoms and delayed diagnosis. Older adults benefit from interventions like percutaneous coronary intervention (PCI) despite underutilization.

Area of Science:

  • Gerontology and Cardiovascular Medicine
  • Internal Medicine
  • Clinical Cardiology

Context:

  • Elderly patients with acute coronary syndrome (ACS) often exhibit non-specific symptoms, leading to delayed medical attention.
  • Older individuals with ACS are less frequently referred for percutaneous coronary intervention (PCI) compared to younger patients.
  • Physiological aging and immunosenescence contribute to atypical presentations and altered pharmacokinetics in elderly patients.

Purpose:

  • To highlight the unique challenges and differences in cardiovascular disease presentation and management in the elderly.
  • To emphasize the benefits of interventions like PCI in elderly populations.
  • To underscore the importance of risk factor management and preventive measures such as vaccinations.

Summary:

  • Acute coronary syndrome in the elderly is characterized by delayed diagnosis due to non-specific symptoms. Despite this, elderly patients, including octogenarians, benefit significantly from percutaneous coronary intervention (PCI) over thrombolysis or drug-only therapy.
  • Stable coronary artery disease management in the elderly prioritizes consistent risk factor control. Systolic heart failure therapy is effective and similar to younger patients, while diastolic heart failure is prevalent.
  • The risk of thrombo-embolic complications in atrial fibrillation escalates with age. Influenza and pneumococcus vaccinations are proven effective in mitigating cardiovascular events in this demographic.

Impact:

  • Improved diagnostic strategies for cardiovascular diseases in the elderly.
  • Increased utilization of effective interventions like PCI in older adults.
  • Enhanced preventive care through risk factor management and vaccination programs, reducing cardiovascular morbidity and mortality.

Related Concept Videos

Drug Dosing: Geriatric Patients01:15

Drug Dosing: Geriatric Patients

Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
Pharmacodynamics in Geriatric Patients: Effects of Age01:27

Pharmacodynamics in Geriatric Patients: Effects of Age

Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
Heart Failure III: Clinical Manifestations01:26

Heart Failure III: Clinical Manifestations

Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
Assessment of the Cardiovascular System I: Subjective Data01:23

Assessment of the Cardiovascular System I: Subjective Data

A thorough health history and physical assessment are essential for identifying cardiovascular disease (CVD) symptoms and distinguishing them from other health issues.
Initial Enquiry
Ask the patient about their primary concern and thoroughly explore all reported symptoms.
Medical History
Investigate past illnesses affecting the cardiovascular system, such as angina, anemia, rheumatic fever, congenital heart disease, stroke, thrombophlebitis, dysrhythmias, varicosities
Inquire about symptoms...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...